Hormonal diagnosis of 21-hydroxylase deficiency in plasma and urine of neonates using benchtop gas chromatography–mass spectrometry

S A Wudy, M Hartmann and J Homoki
Steroid Laboratory, Department of Pediatrics, University of Ulm, Prittwitzstrasse 43, D-89070 Ulm/Donau, Germany
(Requests for offprints should be addressed to S A Wudy)

Abstract

We aimed at measuring the first plasma concentrations of 17-hydroxyprogesterone (17OH-P) determined by benchtop isotope dilution/gas chromatography–mass spectrometry (ID/GC-MS) in term neonates with or without 21-hydroxylase deficiency. Plasma samples from normal cord blood specimens (n=30), unaffected neonates (n=38) and neonatal patients with classical 21-hydroxylase deficiency (eight salt-wasters, three simple virilizers) were analyzed. Steroid profiling of random urinary specimens by GC-MS served as a confirmatory test for 21-hydroxylase deficiency. 17OH-P (nmol/l) in cord blood plasma lay between 11.66 and 75.92 (median 24.74). It declined shortly after birth. In the first 8 days of life, the time that screening for 21-hydroxylase deficiency is performed, 17OH-P ranged between undetected levels and an upper limit of 22.87 (median 4.11). Thereafter (days 9–28) its concentrations lay between 2.18 and 20.30 (median 6.22). Except one simple virilizer, all other patients with 21-hydroxylase deficiency had clearly elevated plasma 17OH-P at the time that screening for 21-hydroxylase deficiency would be performed. We suggest ID/GC-MS, which provides the highest specificity in steroid analysis, for checking suspicious concentrations of 17OH-P in neonates and underscore the potential of urinary steroid profiling by GC-MS as a rapid, non-invasive and non-selective confirmatory test for congenital adrenal hyperplasia.

Journal of Endocrinology (2000) 165, 679–683

Introduction

17-Hydroxyprogesterone (17OH-P, 17α-hydroxyprogren-4-ene-3,20-dione) is the most important plasma parameter for the diagnosis and monitoring of 21-hydroxylase deficiency (New et al. 1989). Currently, neonatal screening procedures for 21-hydroxylase deficiency are based on its determination by immunoassays (Pang & Clark 1990). However, due to cross-reactivity of antibodies, the complex steroid milieu of the newborn human gives rise to considerable variation in the performance of steroid immunoassays (Honour & Rumsby 1993).

Analytical methods based on mass spectrometry present the most specific quantitative methods for steroid determination (Middle 1995). In contrast to immunoassays a physicochemical method like isotope dilution/gas chromatography–mass spectrometry (ID/GC-MS) is independent of cross-reactivity. While the technique has primarily been used as a reference method for the evaluation of steroid immunoassays (Middle 1995) or as a research method, we have developed and suggested clinically applicable procedures employing benchtop instrumentation (Wudy et al. 1992, 1993, 1999).

In the work described in this paper we aimed at providing the first mass spectrometric data on the plasma concentrations of 17OH-P in neonates unaffected or affected with 21-hydroxylase deficiency. GC-MS furthermore permits the chance of urinary steroid profiling, thus presenting a suitable confirmatory procedure after a positive screening test for 21-hydroxylase deficiency in neonates (Honour & Brook 1997).

Patients and Methods

We have studied plasma and random urinary samples collected at the time of diagnosis from 11 term neonates affected with classical 21-hydroxylase deficiency (nine females, two males). Of these, six females and two males had the salt-losing form as shown by typical electrolyte derangements and elevated plasma renin. Apart from one patient (Table 1, patient 7), none had received postnatal treatment. We have furthermore analyzed 30 cord blood plasma samples (mixed cord blood) from term neonates born spontaneously after uneventful pregnancies and plasma specimens from 38 term neonates...
with non-endocrine disorders, of whom none was reported to be critically ill. With the exception of two patients with 21-hydroxylase deficiency (see Tables 1 and 2) none of the neonates investigated had received steroids pre- or postnatally. All urine and plasma specimens were stored at −20 °C until the time of assay. Informed consent was obtained from the parents and the study was approved by the local ethical committee.

Plasma 17OH-P was determined according to our own ID/GC-MS procedure (Wudy et al. 1992). In brief, plasma (0.1–0.5 ml) was equilibrated with 3.03 pmol of a deuterium-labeled analog of the analyte, 17-hydroxy[11,11,12,12-2H4]progesterone, which served as an internal standard. After solvent extraction (ethyl acetate) the dried organic extract was purified on 0.5 g Sephadex LH-20 mini-columns; Pharmacia, Uppsala, Sweden. Then, heptafluorobutyric acid derivatives were prepared and an aliquot (1/12) of the processed plasma extract analyzed by GC/MS. Gas chromatography was carried out on an OV-1 fused silica column (Macherey-Nagel, Düren, Germany; 25 m × 0.20 mm; film thickness 0.1 µm) housed in a DANI 6500 GC (Maine–Kastel, Germany) which was directly interfaced to a Hewlett Packard 5970B (Böhlinger, Germany) mass selective detector operated in the selected ion monitoring mode. Quantification was performed using the peak area ratios between the ion pair of the analyte (m/z 465) and its corresponding internal standard (m/z 469). Intra- and interassay coefficients of variation were 3.5 and 3.8% respectively. The standard plot was linear: \(y = 1.88x + 0.18\); \(r = 0.999\). Concerning sensitivity, 30.26 pmol of 17OH-P gave a signal-to-noise ratio of 5.3. Accuracy was determined by spiking plasma with known amounts of steroids. The agreement between the values found and the amounts added was excellent with a relative error less than 7.5%.

The method used for profiling steroids in urine of newborn infants followed the previously reported routine procedure (Shackleton & Honour 1976, Honour 1986). It consisted of solid phase extraction, separation of free and glucuronidated steroids by LH-20 chromatography, enzymatic hydrolysis, extraction, derivative formation (methylxime-trimethylsilyl-ethers) and GC-MS analysis. Diagnosis of 21-hydroxylase deficiency was based on mass spectrometric identification of four indicative steroids: pregnanetriol (PT, 5β-pregnane-3α,17α,20α-triol), pregnanetriolone (11O-PT, 11-oxo-pregnanetriol, 3α,17α,20α-tri-hydroxy-5β-pregn-11-one), 17-hydroxy-pregnanolone (17OH-PO, 3α,17α-dihydroxy-5β-pregn-20-one) and 15β-hydroxy-pregnanolone (15OH-PO, 3α,15β,17α-tri-hydroxy-5β-pregn-20-one).

**Results**

Application of our ID/GC-MS assay for plasma 17OH-P in a clinical setting is demonstrated by the example of typical ion chromatograms. Figure 1 shows the determination of 17OH-P in 0.1 ml plasma of a normal neonate. The ion traces of the analyte (17OH-P, m/z 465, above) and its corresponding internal standard ([D4]17OH-P, m/z 469, below) have been superposed.
show much fluctuation and did not exceed an upper range limit of 22.87 nmol/l during the whole neonatal period.

Clinical and hormonal data of patients with 21-hydroxylase deficiency are summarized in Table 1 (salt-wasters) and Table 2 (simple virilizers). One simple virilizer had normal 17OH-P on the 4th day of life. All other patients – including a salt-waster in whom hydrocortisone therapy had already been administered for 1 day – had elevated 17OH-P. Urinary steroid analysis confirmed the diagnoses of 21-hydroxylase deficiency by identifying all four indicative steroid metabolites in corresponding random urine specimens.

**Discussion**

Widely divergent plasma levels for 17OH-P in cord blood plasma and plasma of neonates have been published so far; especially, direct immunoassays overestimate 17OH-P concentrations (Forest & Cathiard 1978, Hughes et al. 1979). This is impressively reflected by the considerable variability among cut-off levels of different screening programs (Pang & Clark 1990). It has been demonstrated that the interference of steroid sulfates from the fetal adrenal zone, mainly 17OH-PO sulfate, can lead to false-positive elevated 17OH-P levels (Wong et al. 1992). The production of steroid sulfates in the fetal adrenal zone lasts well into infancy (Shackleton 1984). However, neither solvent extraction nor chromatographic steps necessarily improve the diagnostic efficiency of an immunoassay (Wudy et al. 1994).

These findings are important for screening programs for 21-hydroxylase deficiency, where, for reasons of practicability, direct immunologic procedures are advantageous but are likely to produce false-positive elevated results. In this study, our most important goal was to provide the first data on 17OH-P in neonates unaffected or affected with 21-hydroxylase deficiency using isotope dilution mass spectrometry, currently the most specific method in steroid analysis. Our data in unaffected neonates permit orientation when comparing reference ranges established by immunoassays.

All our patients with the salt-wasting form of 21-hydroxylase deficiency had clearly elevated 17OH-P at the time of diagnosis. In the patient in whom a plasma sample was drawn on day 1, elevated plasma 17OH-P already permitted diagnosis on the 1st day of life (Table 1, patient 1). 17OH-P was still elevated in another patient

---

**Table 1** Hormonal diagnosis of 21-hydroxylase deficiency by mass spectrometry in plasma and urine: salt-wasters

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Prader stage</th>
<th>Plasma specimens</th>
<th>Urinary specimens</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Day of life</td>
<td>17OH-P (nmol/l)</td>
</tr>
<tr>
<td>1</td>
<td>46,XX</td>
<td>4</td>
<td>1</td>
<td>167·9</td>
</tr>
<tr>
<td>2</td>
<td>46,XX</td>
<td>3</td>
<td>5</td>
<td>437·4</td>
</tr>
<tr>
<td>3</td>
<td>46,XX</td>
<td>4</td>
<td>5</td>
<td>66·2</td>
</tr>
<tr>
<td>4*</td>
<td>46,XX</td>
<td>Normal female</td>
<td>5</td>
<td>498·9</td>
</tr>
<tr>
<td>5</td>
<td>46,XY</td>
<td>Normal male</td>
<td>5</td>
<td>1067·7</td>
</tr>
<tr>
<td>6</td>
<td>46,XX</td>
<td>3</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>7**</td>
<td>46,XY</td>
<td>Normal male</td>
<td>19</td>
<td>215·4</td>
</tr>
<tr>
<td>8</td>
<td>46,XX</td>
<td>4</td>
<td>24</td>
<td>41·9</td>
</tr>
</tbody>
</table>

*After prenatal diagnosis and intrauterine dexamethasone treatment.
**Plasma and urine were obtained 1 day after therapy with hydrocortisone had been started.
+Indicates steroid was identified by GC-MS.
who had received hydrocortisone for 1 day because he presented with a life-threatening salt-loss crisis (Table 1, patient 7). Interestingly this patient was missed by prenatal molecular biology testing. Unfortunately, no immediate postnatal confirmation of diagnosis was done and screening for 21-hydroxylase deficiency was not carried out in the area in which the hospital was located.

Patients with the simple virilizing form of 21-hydroxylase deficiency generally had lower 17OHP at the time of diagnosis and affected females had less degree of genital virilization. However, in one case of simple virilizing 21-hydroxylase deficiency, a first specimen on the 4th day of life was normal (Table 2). A second sample obtained 2 days later demonstrated an elevated 17OHP in a virilized female simple virilizer (patient 2, Table 2). This shows that even if screening were performed by the most specific technique, cases of simple virilizers might be missed.

In contrast to procedures merely based on gas chromatography, mass spectrometry permits reliable detection of 21-hydroxylase deficiency by urinary steroid profiling from the first days of life onwards (Honour 1986, Yong et al. 1988). The present study, in which random urine samples have been used, confirms these findings. 17OHP, the marker hormone of 21-hydroxylase deficiency, is catabolized to PT and further to different 17-hydroxypregnanolones like 17OH-PO. Another plasma marker of 21-hydroxylase deficiency, 21-deoxycortisol, is metabolized into 11O-PT. In neonates, steroids like 15OH-PO have been described as unique markers of 21-hydroxylase deficiency (Joannou 1981). Urinary steroid profiling by GC-MS permits the advantage of being non-selective. The technique not only permits detection of all the other virilizing adrenal enzyme defects, 3β-hydroxysteroid dehydrogenase deficiency and 11β-hydroxylase deficiency but also delineates further causes of salt-losing states like lipid adrenal hyperplasia, defects of aldosterone biosynthesis (18-hydroxylase defect, 18-oxidation defect) and congenital adrenal hypoplasia (Honour & Brook 1997, Wudy et al. 1997). After a positive screening test for 21-hydroxylase deficiency, the diagnosis needs to be validated with a confirmatory test. Urinary steroid profiling of random urine specimens by GC-MS seems to be best suited as a confirmatory procedure, because it presents a non-invasive and non-selective procedure with highest specificity. It is rapid, results are available within 3 working days after receipt of sample.

In this study plasma and urinary steroid analyses were done using cost-effective and reliable benchtop GC-MS equipment, demonstrating that mass spectrometric steroid analysis can be performed clinically in a routine setting. Concerning sample throughput, GC-MS of course cannot compete with direct immunoassays and therefore is not suited as a screening procedure. However, individual laboratories with appropriate GC-MS equipment should be able to develop rapid and cost-effective ways of measuring plasma and urinary steroids on a routine basis (Honour 1986, Shackleton et al. 1990, Wudy et al. 1997, 1999).

To conclude, we have presented the first mass spectrometric data on the concentrations of 17OHP in neonates unaffected or affected with 21-hydroxylase deficiency. We speculate that screening for 21-hydroxylase deficiency will detect all cases of salt-wasters but may miss some cases of simple virilizers. GC-MS profiling of urinary steroids provides the opportunity of a non-invasive, rapid, highly specific and non-selective confirmatory test for congenital adrenal hyperplasia.

Acknowledgements

The authors thank Mrs H Pinzer and Mrs E Ambach for excellent technical assistance. S AW acknowledges support by a grant from the Deutsche Forschungsgemeinschaft (DFG WU 148/3).

References


Table 2 Hormonal diagnosis of 21-hydroxylase deficiency by mass spectrometry in plasma and urine: simple virilizers

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Prader stage</th>
<th>Day of life</th>
<th>17OHP (nmol/l)</th>
<th>Day of life</th>
<th>17OHP-PO</th>
<th>15OHP-PO</th>
<th>PT</th>
<th>11O-PT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>46,XX</td>
<td>2</td>
<td>3</td>
<td>73.0</td>
<td>9</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>46,XX</td>
<td>2</td>
<td>4</td>
<td>17.4</td>
<td>No sample available</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>3</td>
<td>46,XX</td>
<td>2</td>
<td>6</td>
<td>122.4</td>
<td>6</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>13</td>
<td>246.0</td>
<td>13</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

†Indicates steroid was identified by GC-MS.


Hughes IA, Riad-Fahmy D & Griffiths K 1979 Plasma 17-hydroxyprogesterone concentrations in newborn infants. Archives of Disease in Childhood 54 347–349.


Received 5 October 1999
Revised manuscript received 24 December 1999
Accepted 27 January 2000